List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2739622/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cutaneous Manifestations of Parkinson's Disease. , 2022, , 187-198.		Ο
2	Dopaminergic medication reduces interhemispheric hyper-synchronization in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 39-46.	2.2	3
3	Exploring the perceptions and stigmatizing experiences of Israeli family caregivers of people with Parkinson's disease. Journal of Aging Studies, 2021, 56, 100910.	1.4	2
4	Patterns of whole-body muscle activations following vertical perturbations during standing and walking. Journal of NeuroEngineering and Rehabilitation, 2021, 18, 75.	4.6	8
5	Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. Movement Disorders, 2019, 34, 1392-1398.		28
6	Coupling Between Leg Muscle Activation and EEG During Normal Walking, Intentional Stops, and Freezing of Gait in Parkinson's Disease. Frontiers in Physiology, 2019, 10, 870.	2.8	23
7	Advanced virtual reality-based rehabilitation of balance and gait in clinical practice. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986837.	2.5	50
8	Excessive phase synchronization in cortical activation during locomotion in persons with Parkinson's disease. Parkinsonism and Related Disorders, 2019, 65, 210-216.	2.2	18
9	Intersegmental coordination patterns are differently affected in Parkinson's disease and cerebellar ataxia. Journal of Neurophysiology, 2019, 121, 672-689.	1.8	10
10	Seeing Gravity: Gait Adaptations to Visual and Physical Inclines – A Virtual Reality Study. Frontiers in Neuroscience, 2019, 13, 1308.	2.8	13
11	Advantages of virtual reality in the rehabilitation of balance and gait. Neurology, 2018, 90, 1017-1025.	1.1	199
12	Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation. Journal of Parkinson's Disease, 2018, 8, 399-403.	2.8	7
13	Gift of creativity with Parkinson's disease. BMJ: British Medical Journal, 2018, 360, k1146.	2.3	0
14	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.8	166
15	Cutaneous squamous cell carcinoma and the PARK2 gene. British Journal of Dermatology, 2017, 177, 323-324.	1.5	1
16	Gait adaptation to conflictive visual flow in virtual environments. , 2017, , .		0
17	Parkinson disease ( <i>PARK</i> ) genes are somatically mutated in cutaneous melanoma. Neurology: Genetics, 2016, 2, e70.	1.9	24
18	Cutaneous malignant melanoma and Parkinson disease: Common pathways?. Annals of Neurology, 2016, 80, 811-820.	5.3	32

#	Article	IF	CITATIONS
19	Micrographia, much beyond the writer's hand. Parkinsonism and Related Disorders, 2016, 26, 1-9.	2.2	28
20	Estimating the Risk for Conversion from Mild Cognitive Impairment to Alzheimer's Disease in an Elderly Arab Community. Journal of Alzheimer's Disease, 2015, 45, 865-871.	2.6	12
21	Higher Frequency of Certain Cancers in <i>LRRK2</i> G2019S Mutation Carriers With Parkinson Disease. JAMA Neurology, 2015, 72, 58.	9.0	76
22	Exploring determinants of progression in Parkinson's disease. Is there a difference among Jewish ethnic groups?. Parkinsonism and Related Disorders, 2015, 21, 184-188.	2.2	2
23	Self-selected gait speed - over ground versus self-paced treadmill walking, a solution for a paradox. Journal of NeuroEngineering and Rehabilitation, 2015, 12, 20.		77
24	Alzheimer's Disease and the Elderly in Israel. American Journal of Alzheimer's Disease and Other Dementias, 2015, 30, 448-453.	1.9	11
25	Genetic Movement Disorders in Patients of Jewish Ancestry. JAMA Neurology, 2014, 71, 1567.	9.0	27
26	The Melanocortin 1 Receptor (Mc1r) Variants Do Not Account for the Co-occurrence of Parkinson's Disease and Malignant Melanoma. Journal of Molecular Neuroscience, 2014, 54, 820-825.	2.3	11
27	Motor progression of Parkinson's disease with the leucineâ€rich repeat kinase 2 G2019S mutation. Movement Disorders, 2014, 29, 1057-1060.	3.9	27
28	Sequence Variants in SLC6A3, DRD2, and BDNF Genes and Time to Levodopa-Induced Dyskinesias in Parkinson's Disease. Journal of Molecular Neuroscience, 2014, 53, 183-188.	2.3	67
29	Enhanced creative thinking under dopaminergic therapy in Parkinson disease. Annals of Neurology, 2014, 75, 935-942.	5.3	57
30	Thalamic–hypothalamic infarction presenting as first-order Horner syndrome. Journal of Neurology, 2013, 260, 1673-1674.	3.6	5
31	Do Tardive Dyskinesia and l-Dopa Induced Dyskinesia Share Common Genetic Risk Factors? An Exploratory Study. Journal of Molecular Neuroscience, 2013, 51, 380-388.	2.3	12
32	The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 1053-1056.	2.2	33
33	Can we climb with our eyes? Preliminary report on the effect of conflicting virtual scenery on leveled and inclined gait. , 2013, , .		4
34	The awakening of artistic creativity and Parkinson's disease Behavioral Neuroscience, 2013, 127, 256-261.	1.2	57
35	Parkinson's Disease Genes Do Not Segregate with Breast Cancer Genes' Loci. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1464-1472.	2.5	3
36	Subthalamic Nucleus Deep Brain Stimulation Does Not Improve Visuo-Motor Impairment in Parkinson's Disease. PLoS ONE, 2013, 8, e65270.	2.5	6

#	Article	IF	CITATIONS
37	Prayer at Midlife is Associated with Reduced Risk of Cognitive Decline in Arabic Women. Current Alzheimer Research, 2013, 10, 340-346.	1.4	33
38	The <i>LRRK2</i> G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology, 2012, 78, 781-786.	1.1	55
39	Identification of Alzheimer disease-associated variants in genes that regulate retromer function. Neurobiology of Aging, 2012, 33, 2231.e15-2231.e30.	3.1	135
40	Dyskinesias in patients with Parkinson's disease: Effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Parkinsonism and Related Disorders, 2012, 18, 1039-1041.		31
41	High Prevalence of Mild Cognitive Impairment and Alzheimer's Disease in Arabic Villages in Northern Israel: Impact of Gender and Education. Journal of Alzheimer's Disease, 2012, 29, 431-439.		47
42	Altered Perceptual Sensitivity to Kinematic Invariants in Parkinson's Disease. PLoS ONE, 2012, 7, e30369.	2.5	10
43	Identification of Novel Candidate Genes for Alzheimer's Disease by Autozygosity Mapping using Genome Wide SNP Data. Journal of Alzheimer's Disease, 2011, 23, 349-359.	2.6	46
44	Benign hereditary chorea: An update. Parkinsonism and Related Disorders, 2011, 17, 301-307.	2.2	45
45	High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. Journal of Neural Transmission, 2011, 118, 1199-1207.	2.8	28
46	Phenotype of the 202 adenine deletion in the <i>parkin</i> gene: 40 years of followâ€up. Movement Disorders, 2011, 26, 719-722.	3.9	8
47	"Double crush―in Parkinson's disease. Annals of Neurology, 2010, 68, 972-972.	5.3	1
48	Mild Cognitive Impairment is Associated with Mild Parkinsonian Signs in a Door-to-Door Study. Journal of Alzheimer's Disease, 2010, 22, 1005-1013.	2.6	16
49	Hypertension Increases the Probability of Alzheimer's Disease and of Mild Cognitive Impairment in an Arab Community in Northern Israel. Neuroepidemiology, 2010, 34, 99-105.	2.3	50
50	Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Archives of Neurology, 2010, 67, 1473.	4.5	376
51	Are genetic and sporadic Parkinson's disease patients equally susceptible to develop dementia?. Journal of the Neurological Sciences, 2010, 289, 23-26.	0.6	20
52	Healthy aging and preclinical dementia: The United States-Israel Longitudinal Database Project. , 2010, 6, 475-481.		5
53	Selective impairment of prediction error signaling in human dorsolateral but not ventral striatum in Parkinson's disease patients: evidence from a model-based fMRI study. NeuroImage, 2010, 49, 772-781.	4.2	78
54	Aggressive familial ALS with unusual brain MRI and a SOD1 gene mutation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 228-231.	2.1	5

#	LE		CITATIONS
55	Essential tremor might be less frequent than Parkinson's disease in North Israel Arab villages. Movement Disorders, 2009, 24, 119-122.	3.9	25
56	The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers. Journal of Neural Transmission, 2009, 116, 1503-1507.		26
57	Dominant vs. Nondominant posterior alien limb—Is it the same phenomenon?. Movement Disorders, 2008, 23, 1060-1062.	3.9	1
58	Psychosis, short stature in benign hereditary chorea: A novel thyroid transcription factorâ€1 mutation. Movement Disorders, 2008, 23, 1744-1747.		43
59	ARE PARKINSON DISEASE PATIENTS PROTECTED FROM SOME BUT NOT ALL CANCERS?. Neurology, 2008, 71, 1650-1651.		14
60	Visuo-Motor Coordination Deficits and Motor Impairments in Parkinson's Disease. PLoS ONE, 2008, 3, e3663.	2.5	40
61	Are Parkinson disease patients protected from some but not all cancers?. Neurology, 2007, 69, 1542-1550.	1.1	112
62	Education effects on cognitive function in a healthy aged Arab population. International Psychogeriatrics, 2007, 19, 593-603.	1.0	39
63	The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nature Genetics, 2007, 39, 168-177.	21.4	1,045
64	Association of Polymorphisms in the Angiotensin-Converting Enzyme Gene with Alzheimer Disease in an Israeli Arab Community. American Journal of Human Genetics, 2006, 78, 871-877.	6.2	69
65	Essential tremor prevalence is low in Arabic villages in Israel. Journal of Neurology, 2006, 253, 1557-1560.	3.6	46
66	Clinicogenetic study of mutations inLRRK2 exon 41 in Parkinson's disease patients from 18 countries. Movement Disorders, 2006, 21, 1102-1108.	3.9	113
67	Association between amantadine and the onset of dementia in Parkinson's disease. Movement Disorders, 2006, 21, 1375-1379.	3.9	66
68	Association between family history of dementia and hallucinations in Parkinson disease. Neurology, 2005, 64, 1712-1715.	1.1	36
69	Inspiratory Muscle Training and the Perception of Dyspnea in Parkinson's Disease. Canadian Journal of Neurological Sciences, 2005, 32, 213-217.	0.5	72
70	Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology, 2005, 65, 1843-1843.	1.1	3
71	Impaired procedural learning in obsessive?compulsive disorder and Parkinson's disease, but not in major depressive disorder. Behavioural Brain Research, 2005, 157, 253-263.	2.2	56
72	OCT and Chronic Papilledema. Ophthalmology, 2005, 112, 2238.e.	5.2	28

#	Article	IF	CITATIONS
73	Onset and progression of disease in familial and sporadic Parkinson's disease. American Journal of Medical Genetics Part A, 2004, 124A, 255-258.	2.4	24
74	Retinal nerve fiber layer thinning in Parkinson disease. Vision Research, 2004, 44, 2793-2797.	1.4	310
75	Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson's disease. Parkinsonism and Related Disorders, 2004, 10, 385-389.	2.2	26
76	Cabergoline, Pramipexole and Ropinirole Used as Monotherapy in Early Parkinson???s Disease. Drugs and Aging, 2003, 20, 847-855.	2.7	43
77	Camptocormia, axial dystonia, and parkinsonism: Phenotypic heterogeneity of a <i>parkin</i> mutation. Neurology, 2003, 60, 1393-1394.		49
78	Respiratory Muscle Performance and the Perception of Dyspnea in Parkinson's Disease. Canadian Journal of Neurological Sciences, 2002, 29, 68-72.	0.5	57
79	Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. Journal of the Neurological Sciences, 2002, 203-204, 81-84.	0.6	50
80	Onset age of Parkinson disease. American Journal of Medical Genetics Part A, 2002, 111, 459-460.	2.4	15
81	Acute Mania and Hemichorea. Clinical Neuropharmacology, 2001, 24, 300-303.	0.7	18
82	<i>Parkin</i> gene causing benign autosomal recessive juvenile parkinsonism. Neurology, 2001, 56, 1573-1575.	1.1	49
83	Mental and Motor Switching in Parkinson's Disease. Journal of Motor Behavior, 2001, 33, 377-385.	0.9	29
84	Transient unilateral mydriasis as the presenting sign of aortic and carotid dissection. Neurology, 2000, 55, 1934-1935.	1.1	12
85	A Comparison of Dopamine Agonists and Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease. Clinical Neuropharmacology, 2000, 23, 262-266.	0.7	20
86	Alien hand sign in Creutzfeldt-Jakob disease. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 103-104.	1.9	25
87	Re: The Apolipoprotein E ε4 Allele Increases the Risk of Drug-Induced Hallucinations in Parkinson's Disease. Clinical Neuropharmacology, 2000, 23, 230-231.	0.7	6
88	Autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: Mutation of <i>Parkin gene</i> . Neurology, 1999, 53, 1602-1602.	1.1	41
89	Apolipoprotein E and Parkinson's disease. Annals of Neurology, 1998, 44, 294-294.	5.3	15
90	A statistical method for quantitative evaluation of the progression of chronic diseases: the mean score graph (MSG). , 1998, 17, 2395-2403.		2

#	Article	IF	CITATIONS
91	Survival in Parkinson's disease: the effect of dementia. Parkinsonism and Related Disorders, 1998, 4, 179-181.	2.2	23
92	Auditory hallucinations in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 533-535.	1.9	159
93	Motor switching abilities in Parkinson's disease and old age: temporal aspects. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 328-337.	1.9	24
94	The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain, 1998, 121, 589-600.	7.6	316
95	Apolipoprotein E4 in Parkinson Disease and Dementia. Alzheimer Disease and Associated Disorders, 1998, 12, 45-48.	1.3	43
96	N30 somatosensory evoked potentials in patients with unilateral Parkinson's disease. Acta Neurologica Scandinavica, 1998, 97, 73-76.	2.1	13
97	Apolipoprotein E ε4 Allele Does Not Influence the Development of Dementia in Parkinsonian Patients. Advances in Behavioral Biology, 1998, , 817-821.	0.2	1
98	Falls in elderly people. Lancet, The, 1997, 349, 1180.	13.7	3
99	Letters to the editor. Movement Disorders, 1996, 11, 115-116.	3.9	19
100	Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology, 1996, 47, 785-788.	1.1	78
101	MATTERS ARISING: Inzelberg and Korczyn reply:. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 247-247.	1.9	Ο
102	Switching abilities in Parkinson's disease. Advances in Neurology, 1996, 69, 361-9.	0.8	6
103	Changes in excitability of motor cortical circuitry in patients with parkinson's disease. Annals of Neurology, 1995, 37, 181-188.	5.3	524
104	Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. Movement Disorders, 1995, 10, 604-607.	3.9	16
105	MATTERS ARISING: Inzelberg and Korczyn reply:. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 645-647.	1.9	2
106	Kinematic properties of upper limb trajectories in idiopathic torsion dystonia Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 312-319.	1.9	57
107	Changes in the balance between motor cortical excitation and inhibition in focal, task specific dystonia Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 493-498.	1.9	533
108	Kinematic Analysis of Complex Movements in Parkinson's Disease. , 1995, , 181-187.		1

#	Article		CITATIONS
109	Natural Course of Idiopathic Torsion Dystonia among Jews. Neuroepidemiology, 1994, 13, 195-201.	2.3	7
110	Persistent hemiballism in Parkinson's disease Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1013-1014.	1.9	19
111	Parkinsonism in adult-onset GM2 gangliosidosis. Movement Disorders, 1994, 9, 375-377.	3.9	36
112	Basal Ganglia Lacunes and Parkinsonism. Neuroepidemiology, 1994, 13, 108-112.	2.3	45
113	Laterality of onset in idiopathic torsion dystonia. Movement Disorders, 1993, 8, 327-330.	3.9	9
114	Transient musical hallucinosis Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 833-833.	1.9	19
115	Dystonia. Current Opinion in Neurology and Neurosurgery, 1993, 6, 350-7.	0.4	6
116	The Lupus Anticoagulant and Dementia in Non-SLE Patients. Dementia and Geriatric Cognitive Disorders, 1992, 3, 140-145.	1.5	6
117	Timing and sequencing of human arm trajectories: Normal and abnormal motor behaviour. Human Movement Science, 1992, 11, 83-100.	1.4	23
118	Kinematic analysis of upper limb trajectories in Parkinson's disease. Experimental Neurology, 1992, 118, 215-226.	4.1	124
119	Dementia in non-SLE patients with lupus anticoagulant. Journal of Neuroimmunology, 1991, 35, 39.	2.3	0
120	Effects of Atropine on Learning and Memory Functions in Dementia. Clinical Neuropharmacology, 1990, 13, 241-247.	0.7	16
121	Kinematic properties of upper-limb trajectories in Parkinson's disease and idiopathic torsion dystonia. Advances in Neurology, 1990, 53, 183-9.	0.8	44
122	Lupus anticoagulant and late onset seizures. Acta Neurologica Scandinavica, 1989, 79, 114-118.	2.1	57
123	Cerebrovascular symptoms in thromboangiitis obliterans. Acta Neurologica Scandinavica, 1989, 80, 347-350.	2.1	11
124	Non surgical treatment of subdural hematoma in a hemodialysis patient. Clinical Neurology and Neurosurgery, 1989, 91, 85-89.	1.4	20
125	EEG in demented and non-demented parkinsonian patients. Acta Neurologica Scandinavica, 1988, 78, 1-5.	2.1	104
126	Clinical course of idiopathic torsion dystonia among Jews in Israel. Advances in Neurology, 1988, 50, 93-100.	0.8	6

		Rivka Inzelberg	
#	Article	IF	CITATIONS
127	Computed tomography brain changes in Parkinsonian dementia. Neuroradiology, 1987, 29,	535-539. 2.2	16

128 Current Status of Pharmacogenetics in Antithrombotic Drug Therapy., 0,,.